ContraFect

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ContraFect and other ETFs, options, and stocks.

About CFRX

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides. 

CEO
Roger J. Pomerantz
CEORoger J. Pomerantz
Employees
38
Employees38
Headquarters
Yonkers, New York
HeadquartersYonkers, New York
Founded
2008
Founded2008
Employees
38
Employees38

CFRX Key Statistics

Market cap
5.96M
Market cap5.96M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
1.28M
Average volume1.28M
High today
$0.1624
High today$0.1624
Low today
$0.146
Low today$0.146
Open price
$0.151
Open price$0.151
Volume
876.78K
Volume876.78K
52 Week high
$4.54
52 Week high$4.54
52 Week low
$0.1275
52 Week low$0.1275

CFRX News

Yahoo Finance 2d
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections - Yahoo Finance

ContraFect Corporation YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused o...

ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections - Yahoo Finance

CFRX Earnings

-$0.51
-$0.34
-$0.17
$0.00
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Mar 23, Pre-Market
ActualExpected Mar 23, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.